Welcome to our dedicated page for Telomir Pharms SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals (NASDAQ: TELO) signed a binding LOI to acquire TELI Pharmaceuticals in a stock-for-stock deal, consolidating worldwide intellectual property and development rights to its lead candidate, Telomir-1.
The agreement includes up to $5 million in cash contributions from certain TELI shareholders: $1 million at closing, $2 million upon FDA acceptance of an IND, and $2 million upon initiation of a Phase 1/2 study. Shares tied to the $4 million in milestone contributions will be allocated at closing and issued upon receipt of each payment. Closing is not contingent on receiving the milestone funds.
The LOI imposes a six-month lockup on shares issued to TELI holders and is subject to due diligence, board and stockholder approvals, regulatory clearances, and definitive agreements. If completed, Telomir would hold unified global rights to Telomir-1, aiming to simplify development and partnering.
Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical findings showing that its small molecule Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. The compound produced a concentration-dependent decrease in cell viability and mitochondrial activity, aligning with prior results in triple‑negative breast and prostate cancer models.
The response in pancreatic cells was partially reversed by iron re‑addition, indicating iron‑dependent processes contribute to the effect, while incomplete rescue suggests additional metabolic or epigenetic mechanisms. Telomir-1 has been associated with tumor suppressor genes and iron‑dependent histone demethylases relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B, and KDM6B. The company noted pancreatic cancer’s five‑year survival rate is about 12 percent. Telomir plans to expand preclinical research to additional models, including leukemia, and to initiate in vivo validation studies as part of ongoing IND preparation.
Telomir Pharmaceuticals, Inc. reported new preclinical findings showing that its compound Telomir-1 selectively kills aggressive triple-negative breast cancer (TNBC) cells in laboratory studies. As Telomir-1 concentrations increased in human TNBC cell models, cancer cell survival dropped in a clear, concentration-dependent manner, and adding iron back restored cell growth, indicating the effect is tied to iron-dependent energy regulation.
The company explains that TNBC cells are highly metabolically active and rely heavily on iron, and that Telomir-1 appears to exploit this vulnerability while normal cells manage iron differently. Telomir-1 has also been shown previously to reset abnormal DNA methylation patterns, and the new data suggest its impact on TNBC may involve iron-dependent epigenetic enzymes linked to aggressive behavior and treatment resistance. Telomir plans to expand these studies to other cancer types and perform additional animal studies as it prepares an Investigational New Drug submission.
Telomir Pharmaceuticals, Inc. reported new preclinical findings for its lead investigational compound, Telomir-1, in aggressive prostate cancer models. The studies showed that Telomir-1 can reset abnormal DNA methylation and restore the function of two key tumor suppressor genes, MASPIN and RASSF1A, which are often silenced in cancer and are closely linked to metastasis and treatment resistance.
In an in vivo aggressive prostate cancer model, MASPIN was silenced by DNA hypermethylation, and Telomir-1 reversed chemotherapy-induced DNA methylation to restore MASPIN activity. Telomir-1 also reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy. The company states that reactivating these genes may help restore natural tumor defenses, counteract chemotherapy-induced resistance, and limit cancer metastasis as part of its ongoing preclinical and IND-enabling development of Telomir-1.
John Paul DeJoria, both personally and as trustee of the John Paul DeJoria Family Trust, reports beneficial ownership of 1,774,900 shares of Telomir Pharmaceuticals, Inc. common stock, representing 5.50% of the outstanding class. The filing indicates Mr. DeJoria has sole voting and dispositive power over these shares and states the shares were not acquired to change or influence control of the company. The filing lists the issuer's principal office in Miami, FL, and provides a business address for the reporting person in Georgetown, TX. A power of attorney is attached as an exhibit.
Telomir Pharmaceuticals reported new in vitro pharmacology data for its lead candidate Telomir-1, showing that the drug potently inhibits three members of the KDM5 histone demethylase family. These enzymes help cancers and aging cells silence protective genes and activate harmful inflammatory pathways.
The company notes that Telomir-1 had already demonstrated activity against other histone demethylases, including UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A), while sparing broad acetyltransferases linked to systemic toxicity. In earlier in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressor genes such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin.
Taken together, Telomir-1 is described as having broad-spectrum activity across DNA methylation and multiple histone demethylation pathways, supporting ongoing IND-enabling studies, GMP scale-up, and additional preclinical work in aggressive cancers and aging models.
Telomir Pharmaceuticals reported new preclinical results in aggressive human prostate cancer cell models showing that its investigational therapy Telomir-1 reverses DNA methylation–driven silencing of CDKN2A, a key tumor suppressor often described as the body’s natural “cell cycle brake.” In these PC3 xenograft models, Telomir-1 inhibited DNA hypermethylation of CDKN2A and outperformed both Rapamycin and chemotherapy on this measure.
The company notes that earlier data showed Telomir-1 also resets DNA methylation of STAT1, a master immune regulator. Together, the STAT1 and CDKN2A findings suggest Telomir-1 can reset epigenetic silencing across multiple tumor suppressor and immune pathways. Telomir is evaluating Telomir-1 in several aggressive cancer types and continues its pre-IND work, including CMC scale-up toward GMP production and IND-enabling studies ahead of a planned first IND submission.
Telomir Pharmaceuticals, Inc. completed an at-the-market equity offering on August 28, 2025, selling 1,550,000 shares of common stock in block trades to institutional investors at an average price of $1.87 per share. This generated gross proceeds of approximately $2.9 million before fees and expenses. The sales were executed through Rodman & Renshaw using the StockBlock platform and did not include any warrants.
Telomir Pharmaceuticals filed an update on new laboratory data for its lead preclinical drug candidate, Telomir-1, which targets the biology of cancer, aging, and age-related diseases. In in vitro studies run by Eurofins Discovery, Telomir-1 potently inhibited the histone demethylase UTX (KDM6A), an enzyme tied to abnormal DNA methylation patterns that can silence tumor suppressors and activate disease-driving genes. By blocking UTX, the compound showed potential to help reset faulty gene regulation.
The company notes prior findings that Telomir-1 inhibits other epigenetic enzymes FBXL10, FBXL11, and JMJD3, and can reactivate silenced tumor suppressors such as STAT1 and TMS1 in prostate cancer models. The new data also highlight selectivity: Telomir-1 showed no activity against the broad acetyltransferase GCN5L2 (KAT2A), which is associated with toxicity when inhibited. It did show low-level inhibition of Tankyrases (PARP5A and PARP5B), suggesting modest interference with Wnt/β-catenin “fuel line” signaling that cancers use for growth. Overall, the results support Telomir-1’s profile as a potential first-in-class epigenetic therapy with a dual mechanism of resetting DNA methylation pathways and modestly impacting Wnt/Tankyrase signaling.